Company intelligence / Profile preview

Hangzhou SynoMed Pharmaceuticals

Hangzhou, Zhejiang, China

Ownership: Private
Development stage: Other

Overview

Hangzhou SynoMed Pharmaceuticals is a clinical-stage biopharmaceutical company based in Hangzhou, China, specializing in the discovery and development of innovative small molecule drugs for metabolic and inflammatory diseases. The company's lead program, Syno-2101, is a potent and selective URAT1 inhibitor currently in Phase 2 clinical trials for the treatment of gout and hyperuricemia. SynoMed focuses on addressing significant unmet medical needs in the metabolic space through its internal R&D capabilities and experienced scientific team. The company aims to provide safer and more effective therapeutic options for patients suffering from chronic metabolic conditions.

Therapeutic areas: RheumatologyMetabolic Disorders
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Hangzhou SynoMed Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hangzhou SynoMed Pharmaceuticals.

Explore the full profile